AbbVie Soars 3.67% on Strong Q2 Earnings, Guidance Hike

On July 31, 2025, AbbVie's stock rose 3.67% in pre-market trading, reflecting positive investor sentiment and recent developments within the company.

AbbVie has announced an upward revision to its full-year adjusted diluted EPS guidance, now ranging from $11.88 to $12.08, up from the previous range of $11.67 to $11.87. This adjustment includes an unfavorable impact of $0.55 per share related to acquired IPR&D and milestones expense incurred year-to-date through the second quarter of 2025.

In the second quarter, AbbVie reported strong financial performance with global net revenues of $15.423 billion, a 6.6% increase on a reported basis. The company's immunology portfolio, which includes key products like Skyrizi and Rinvoq, saw significant growth, with global net revenues increasing by 9.5% on a reported basis. The neuroscience portfolio also performed well, with global net revenues up by 24.2% on a reported basis, driven by products like Vraylar and Botox Therapeutic.

AbbVie's JAK inhibitor Rinvoq (upadacitinib) achieved positive results in a Phase 3 clinical trial for alopecia areata, demonstrating significant hair regrowth in patients. This success highlights the potential of Rinvoq in expanding its therapeutic indications and strengthening AbbVie's position in the dermatology market.

Additionally, AbbVie is in discussions to acquire Gilgamesh Pharmaceuticals, a company focused on developing new treatments for mental health conditions. This potential acquisition aligns with AbbVie's strategy to enhance its product pipeline in the mental health sector, following a previous collaboration with Gilgamesh on developing new therapies for psychiatric disorders.